{"id":11019,"date":"2025-10-30T08:50:51","date_gmt":"2025-10-30T07:50:51","guid":{"rendered":"http:\/\/localhost\/fda-ia-farmaceutica-rascunho-2025\/"},"modified":"2025-10-30T08:50:51","modified_gmt":"2025-10-30T07:50:51","slug":"fda-ia-farmaceutica-rascunho-2025","status":"publish","type":"post","link":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/","title":{"rendered":"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.14.7&#8243; width=&#8221;100%&#8221; max_width=&#8221;76%&#8221; module_alignment=&#8221;left&#8221; custom_margin=&#8221;|-155px||||&#8221; custom_padding=&#8221;0px|||||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||2px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#000000&#8243; header_font=&#8221;Montserrat||||||||&#8221; header_font_size=&#8221;14px&#8221; header_line_height=&#8221;1.5em&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;|75px|18px|1px||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: justify;\">A <strong>FDA coloca a credibilidade como condi\u00e7\u00e3o indispens\u00e1vel para utilizar IA<\/strong> em decis\u00f5es regulamentares farmac\u00eauticas, num quadro proporcional ao risco que exige rastreabilidade, transpar\u00eancia e valida\u00e7\u00e3o ao longo de todo o ciclo de vida do modelo. Esta abordagem foi sintetizada e divulgada por <strong>Guillem L\u00f3pez, CSV &#038; QA Manager da OYTEC<\/strong>, autor da an\u00e1lise <strong>&#8220;Credibilidad de la IA farmac\u00e9utica: Claves del borrador de la FDA&#8221; (Credibilidade da IA farmac\u00eautica: aspetos-chave do rascunho da FDA)<\/strong> publicado no n\u00famero 18 da revista FARMABIOTEC.<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; min_height=&#8221;481.5px&#8221; custom_margin=&#8221;-20px||-50px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/oytec.es\/wp-content\/uploads\/Captura-revista-Guillem-800&#215;561.png&#8221; title_text=&#8221;OYTEC-FDA-Guillem&#8221; align=&#8221;center&#8221; align_tablet=&#8221;center&#8221; align_phone=&#8221;&#8221; align_last_edited=&#8221;on|desktop&#8221; _builder_version=&#8221;4.14.7&#8243; max_width=&#8221;40%&#8221; module_alignment=&#8221;center&#8221; min_height_tablet=&#8221;500px&#8221; min_height_phone=&#8221;500px&#8221; min_height_last_edited=&#8221;off|desktop&#8221; custom_margin=&#8221;|44px|37px|||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;3_4,1_4&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;2px||2px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#000000&#8243; header_2_font_size=&#8221;22px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; custom_padding=&#8221;|0px||65px||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 style=\"text-align: justify;\"><span style=\"color: #000000;\">Exig\u00eancias regulamentares<\/span><\/h2>\n<p>O rascunho <strong>\u201cConsiderations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products\u201d<\/strong>, emitido em janeiro de 2025, estabelece que deve ser definido um quadro de credibilidade dos modelos ajustado ao risco deste processo, tendo em conta tanto a influ\u00eancia que o modelo ter\u00e1 na tomada de decis\u00f5es como as consequ\u00eancias que teria a tomada de uma decis\u00e3o incorreta (Model influence vs. Decision consequence).<br \/>\n[\/et_pb_text][et_pb_text _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#000000&#8243; header_2_font_size=&#8221;22px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; width=&#8221;100%&#8221; custom_padding=&#8221;|0px||65px||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<strong>Prop\u00f5e-se a elabora\u00e7\u00e3o de um plano para estabelecer a credibilidade<\/strong> e de um relat\u00f3rio correspondente que demonstre a idoneidade do modelo para o contexto de utiliza\u00e7\u00e3o. Entre os elementos-chave do plano<strong> dever\u00e1 estar inclu\u00edda a defini\u00e7\u00e3o da pergunta de interesse, o contexto de utiliza\u00e7\u00e3o, a avalia\u00e7\u00e3o do risco e a descri\u00e7\u00e3o t\u00e9cnica de como o modelo foi desenvolvido<\/strong> <strong>(incluindo dados, o treino e as m\u00e9tricas de avalia\u00e7\u00e3o, entre outros).<\/strong> Uma vez estabelecido, dever\u00e1 ser executado e dever\u00e1 registar-se adequadamente a adequa\u00e7\u00e3o dos resultados ao contexto de utiliza\u00e7\u00e3o.<br \/>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/oytec.es\/wp-content\/uploads\/Grafica-riesgo-Guillem.png&#8221; title_text=&#8221;Grafica-riesgo-Guillem&#8221; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; transform_scale=&#8221;95%|95%&#8221; transform_translate=&#8221;-24px|28px&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row module_class=&#8221; et_pb_row_fullwidth&#8221; _builder_version=&#8221;3.25&#8243; width=&#8221;89%&#8221; width_tablet=&#8221;80%&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|desktop&#8221; max_width=&#8221;89%&#8221; max_width_tablet=&#8221;80%&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|desktop&#8221; min_height=&#8221;877.5px&#8221; custom_padding=&#8221;8px|||||&#8221; z_index_tablet=&#8221;500&#8243; make_fullwidth=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/oytec.es\/wp-content\/uploads\/Diagrama-ejemplo-de-entrenamiento-de-una-red-neuronal-800&#215;435.png&#8221; title_text=&#8221;Diagrama ejemplo de entrenamiento de una red neuronal&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;27px|||||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#000000&#8243; header_2_font_size=&#8221;22px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; min_height=&#8221;72px&#8221; custom_margin=&#8221;-18px|||||&#8221; custom_padding=&#8221;19px|0px||0px||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Como em qualquer sistema GMP cr\u00edtico, uma vez em fase produtiva, n\u00e3o deve faltar o<strong> planeamento da manuten\u00e7\u00e3o e a revis\u00e3o peri\u00f3dica do desempenho<\/strong>. Mas, no caso dos modelos de IA, \u00e9 especialmente importante, por se tratar de sistemas que aprendem com o nosso processo, e este est\u00e1 em constante evolu\u00e7\u00e3o (fen\u00f3meno do Data drift). \u00c9 crucial assegurar que esta adequa\u00e7\u00e3o ao contexto de utiliza\u00e7\u00e3o se mant\u00e9m atrav\u00e9s da monitoriza\u00e7\u00e3o e do retreino.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#000000&#8243; header_2_text_color=&#8221;#000000&#8243; header_2_font_size=&#8221;22px&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; custom_padding=&#8221;|2px||0px||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Contributo da OYTEC e do seu autor<\/h2>\n<p>Na OYTEC, Guillem L\u00f3pez destaca a necessidade de <strong>identificar com precis\u00e3o a pergunta de interesse (QoI) e o contexto de utiliza\u00e7\u00e3o<\/strong> para poder estabelecer um <em>Credibility Assessment Plan<\/em> e um <em>Credibility Assessment Report <\/em>que liguem a evid\u00eancia t\u00e9cnica \u00e0 adequa\u00e7\u00e3o \u00e0s necessidades da f\u00e1brica, integrando a regulamenta\u00e7\u00e3o GxP e referenciais como o GAMP5 Ed.2 e a ISPE, para assegurar a reprodutibilidade e o controlo de altera\u00e7\u00f5es.<\/p>\n<\/p>\n<h2>Como a OYTEC implementa a IA<\/h2>\n<p>A OYTEC implementa <strong>solu\u00e7\u00f5es de IA em ambientes GxP juntamente com parceiros tecnol\u00f3gicos como a Aizon<\/strong>, alinhando planos e relat\u00f3rios de credibilidade com o quadro da FDA.<\/p>\n<p>Para aprofundar, pode consultar <a href=\"https:\/\/oytec.es\/wp-content\/uploads\/Revista-Farmabiotec-Numero-18-66-71.pdf\" target=\"_blank\" rel=\"noopener\">o artigo de Guillem L\u00f3pez na FARMABIOTEC (n.\u00ba 18, p\u00e1gs. 66\u201371)<\/a> e contactar os <a href=\"https:\/\/www.oytec.es\/pt\/contacto\/\" target=\"_blank\" rel=\"noopener\">nossos especialistas.<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22&#8243; custom_padding=&#8221;9px|||||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row module_class=&#8221; et_pb_row_fullwidth&#8221; _builder_version=&#8221;3.25&#8243; width=&#8221;89%&#8221; width_tablet=&#8221;80%&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|desktop&#8221; max_width=&#8221;89%&#8221; max_width_tablet=&#8221;80%&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|desktop&#8221; custom_padding=&#8221;11px|0px|38.0469px|0px|false|false&#8221; z_index_tablet=&#8221;500&#8243; make_fullwidth=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_divider _builder_version=&#8221;3.21.4&#8243; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][et_pb_text _builder_version=&#8221;3.27.4&#8243; text_font=&#8221;Roboto||||||||&#8221; text_text_color=&#8221;#000000&#8243; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<strong style=\"color: #333333; font-size: 22px;\">\u00daltimas Not\u00edcias<\/strong><br \/>\n[\/et_pb_text][et_pb_blog fullwidth=&#8221;off&#8221; posts_number=&#8221;3&#8243; include_categories=&#8221;3,5,17,7&#8243; show_more=&#8221;on&#8221; show_date=&#8221;off&#8221; _builder_version=&#8221;3.21.4&#8243; z_index_tablet=&#8221;500&#8243; box_shadow_style=&#8221;preset3&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_blog][et_pb_button button_url=&#8221;https:\/\/oytec.es\/blog-oytec\/&#8221; button_text=&#8221;Mais not\u00edcias&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.14.7&#8243; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#eef1f7&#8243; background_image=&#8221;https:\/\/www.oytec.es\/wp-content\/uploads\/2021\/03\/Footer_Oytec_400.jpg&#8221; background_enable_image=&#8221;off&#8221; custom_margin=&#8221;||-55px|||&#8221; custom_padding=&#8221;3px||3px|||&#8221; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_5,1_5,1_5,1_5,1_5&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.9.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-9px||20px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<strong>BARCELONA<\/strong><br \/>\n[\/et_pb_text][et_pb_text admin_label=&#8221;Texto&#8221; _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Roboto||||||||&#8221; text_text_color=&#8221;#636363&#8243; header_3_font=&#8221;|||on|||||&#8221; header_6_text_color=&#8221;#7c7c7c&#8221; background_layout=&#8221;dark&#8221; custom_padding=&#8221;0px|||||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<aside>@SANTCUGAT building<\/aside>\n<aside>Av. Via Augusta, 15-25<\/aside>\n<aside>08174 Sant Cugat del Vall\u00e8s<\/aside>\n<aside>Barcelona, ES<\/aside>\n<aside>+34 610 459 081<\/aside>\n<aside>\n<div>\n<div>\n<p>info@oytec.es<\/p>\n<\/div>\n<\/div>\n<\/aside>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.9.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;-9px||20px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<strong>MADRID<\/strong><br \/>\n[\/et_pb_text][et_pb_text admin_label=&#8221;Texto&#8221; _builder_version=&#8221;4.14.7&#8243; text_font=&#8221;Roboto||||||||&#8221; text_text_color=&#8221;#636363&#8243; header_3_font=&#8221;|||on|||||&#8221; header_6_text_color=&#8221;#7c7c7c&#8221; background_layout=&#8221;dark&#8221; custom_padding=&#8221;0px|||||&#8221; z_index_tablet=&#8221;500&#8243; global_colors_info=&#8221;{}&#8221;]Carretera M-603 Fuencarral a Alcobendas Portal n\u00ba 44, Edificio 6, Piso Bajo, Puerta 23 28108, Alcobendas, Madrid<br \/>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.9.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/oytec.es\/wp-content\/uploads\/2023\/06\/CertificadoER-0524-2021_ES_2021-10-19-1.jpg&#8221; title_text=&#8221;CertificadoER-0524-2021_ES_2021-10-19-1&#8243; show_in_lightbox=&#8221;on&#8221; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; width=&#8221;50%&#8221; max_width=&#8221;50%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/oytec.es\/wp-content\/uploads\/2023\/06\/IQNetES-0524-2021_2021-10-19-1.jpg&#8221; title_text=&#8221;IQNetES-0524-2021_2021-10-19-1&#8243; show_in_lightbox=&#8221;on&#8221; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; width=&#8221;50%&#8221; max_width=&#8221;50%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_5&#8243; _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.14.7&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(255,255,255,0)&#8221; custom_margin=&#8221;-6px|||||&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: right;\"><span style=\"color: #808080;\"><a style=\"color: #808080;\" href=\"https:\/\/www.oytec.es\/pt\/contacto\/\">CONTACT<\/a><\/span><\/p>\n<p style=\"text-align: right;\"><span style=\"color: #808080;\"><a style=\"color: #808080;\" href=\"https:\/\/www.oytec.es\/pt\/blog\/\">BLOG<\/a><\/span><\/p>\n<p style=\"text-align: right;\"><a href=\"https:\/\/www.oytec.es\/pt\/legal\/\"><span style=\"color: #808080;\">LEGAL<\/span><\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A FDA coloca a credibilidade como condi\u00e7\u00e3o indispens\u00e1vel para utilizar IA em decis\u00f5es regulamentares farmac\u00eauticas, num quadro proporcional ao risco que exige rastreabilidade, transpar\u00eancia e valida\u00e7\u00e3o ao longo de todo o ciclo de vida do modelo. Esta abordagem foi sintetizada e divulgada por Guillem L\u00f3pez, CSV &#038; QA Manager da OYTEC, autor da an\u00e1lise &#8220;Credibilidad [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10452,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p><a style=\"font-size: 14px;\" href=\"https:\/\/oytec.es\/wp-content\/uploads\/Revista-Farmabiotec-Numero-18-66-71.pdf\"><img class=\"wp-image-10242 aligncenter\" src=\"https:\/\/oytec.es\/wp-content\/uploads\/Captura-revista-Guillem-800x561.png\" alt=\"\" width=\"445\" height=\"312\" \/><\/a>La FDA sit\u00faa la credibilidad como condici\u00f3n indispensable para utilizar IA en decisiones regulatorias farmac\u00e9uticas, en un marco proporcional al riesgo que exige trazabilidad, transparencia y validaci\u00f3n a lo largo de todo el ciclo de vida del modelo. Este enfoque ha sido sintetizado y divulgado por Guillem L\u00f3pez, CSV & QA Manager de OYTEC, autor del an\u00e1lisis publicado en el n\u00famero 18 de la revista FARMABIOTEC.<\/p><h2>Exigencias regulatorias<\/h2><p>El borrador emitido en enero de 2025 define que el rigor de la evaluaci\u00f3n debe ajustarse a la influencia del modelo en la decisi\u00f3n y a la severidad de sus consecuencias, articulando un plan de credibilidad y un reporte final que demuestre idoneidad para el contexto de uso. Entre los elementos clave se incluyen la definici\u00f3n de la pregunta de inter\u00e9s, el contexto de uso, la estratificaci\u00f3n de riesgo, la descripci\u00f3n t\u00e9cnica del modelo y datos, la validaci\u00f3n con m\u00e9tricas justificadas y la planificaci\u00f3n de mantenimiento y monitorizaci\u00f3n del desempe\u00f1o.<\/p><h2>Aportaci\u00f3n de OYTEC y su autor<\/h2><p>Desde OYTEC, Guillem L\u00f3pez destaca la necesidad de un <em>Credibility Assessment Plan<\/em> y un <em>Credibility Assessment Report<\/em> que conecten evidencia t\u00e9cnica con la toma de decisiones reguladas, integrando GxP y marcos como GAMP5 Ed.2 e ISPE para asegurar reproducibilidad y control del cambio.<\/p><h2>OYTEC y la IA, los partners<\/h2><p>OYTEC implementa soluciones de IA en entornos GxP junto a partners tecnol\u00f3gicos como Aizon, alineando planes y reportes de credibilidad con el marco FDA para asegurar trazabilidad, detecci\u00f3n de sesgos y vigilancia de drift post\u2011despliegue.<\/p><p>Para profundizar, puede consultar el art\u00edculo de Guillem L\u00f3pez en FARMABIOTEC (n\u00ba18, p\u00e1gs. 66\u201371)<a href=\"https:\/\/oytec.es\/wp-content\/uploads\/Revista-Farmabiotec-Numero-18-66-71.pdf\" target=\"_blank\" rel=\"noopener\"> Revista Farmabiotec - N\u00famero 18-66-71<\/a><\/p>","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","footnotes":""},"categories":[209,210],"tags":[214,212,217,216],"class_list":["post-11019","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-digitalizacao","category-transformacao-digital","tag-214","tag-divulgacao","tag-fda","tag-ia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos OYTEC<\/title>\n<meta name=\"description\" content=\"Descubra os aspetos-chave do Rascunho de 2025 da FDA sobre a credibilidade da IA farmac\u00eautica e o seu impacto na regulamenta\u00e7\u00e3o.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos OYTEC\" \/>\n<meta property=\"og:description\" content=\"Descubra os aspetos-chave do Rascunho de 2025 da FDA sobre a credibilidade da IA farmac\u00eautica e o seu impacto na regulamenta\u00e7\u00e3o.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"OYTEC\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T07:50:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.oytec.es\/wp-content\/uploads\/fda-draft-ai-2025.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1632\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"OYTEC\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@OYTEC_MES\" \/>\n<meta name=\"twitter:site\" content=\"@OYTEC_MES\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"OYTEC\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/\"},\"author\":{\"name\":\"OYTEC\",\"@id\":\"https:\\\/\\\/oytec.es\\\/#\\\/schema\\\/person\\\/7139c1ebb2602be7f35ca9e9b357fafa\"},\"headline\":\"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos\",\"datePublished\":\"2025-10-30T07:50:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/\"},\"wordCount\":1607,\"publisher\":{\"@id\":\"https:\\\/\\\/oytec.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.oytec.es\\\/wp-content\\\/uploads\\\/fda-draft-ai-2025.png\",\"keywords\":[\"2025\",\"Divulga\u00e7\u00e3o\",\"FDA\",\"IA\"],\"articleSection\":[\"Digitaliza\u00e7\u00e3o\",\"Transforma\u00e7\u00e3o Digital\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/\",\"url\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/\",\"name\":\"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos OYTEC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oytec.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.oytec.es\\\/wp-content\\\/uploads\\\/fda-draft-ai-2025.png\",\"datePublished\":\"2025-10-30T07:50:51+00:00\",\"description\":\"Descubra os aspetos-chave do Rascunho de 2025 da FDA sobre a credibilidade da IA farmac\u00eautica e o seu impacto na regulamenta\u00e7\u00e3o.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.oytec.es\\\/wp-content\\\/uploads\\\/fda-draft-ai-2025.png\",\"contentUrl\":\"https:\\\/\\\/www.oytec.es\\\/wp-content\\\/uploads\\\/fda-draft-ai-2025.png\",\"width\":1632,\"height\":640},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/fda-ia-farmaceutica-rascunho-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.oytec.es\\\/pt\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oytec.es\\\/#website\",\"url\":\"https:\\\/\\\/oytec.es\\\/\",\"name\":\"OYTEC\",\"description\":\"Digitalizando las operaciones Farma 4.0\",\"publisher\":{\"@id\":\"https:\\\/\\\/oytec.es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oytec.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/oytec.es\\\/#organization\",\"name\":\"OYTEC\",\"url\":\"https:\\\/\\\/oytec.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/oytec.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/oytec.es\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/cropped-OYTEC-Logo-transparent.png\",\"contentUrl\":\"https:\\\/\\\/oytec.es\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/cropped-OYTEC-Logo-transparent.png\",\"width\":175,\"height\":45,\"caption\":\"OYTEC\"},\"image\":{\"@id\":\"https:\\\/\\\/oytec.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/OYTEC_MES\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/oytec\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oytec.es\\\/#\\\/schema\\\/person\\\/7139c1ebb2602be7f35ca9e9b357fafa\",\"name\":\"OYTEC\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed13085cc0eeaa48d287170c1bdf9b17c35a4ece8c00f8713ac9b1483411d958?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed13085cc0eeaa48d287170c1bdf9b17c35a4ece8c00f8713ac9b1483411d958?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed13085cc0eeaa48d287170c1bdf9b17c35a4ece8c00f8713ac9b1483411d958?s=96&d=mm&r=g\",\"caption\":\"OYTEC\"},\"sameAs\":[\"https:\\\/\\\/oytec.es\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos OYTEC","description":"Descubra os aspetos-chave do Rascunho de 2025 da FDA sobre a credibilidade da IA farmac\u00eautica e o seu impacto na regulamenta\u00e7\u00e3o.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/","og_locale":"pt_PT","og_type":"article","og_title":"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos OYTEC","og_description":"Descubra os aspetos-chave do Rascunho de 2025 da FDA sobre a credibilidade da IA farmac\u00eautica e o seu impacto na regulamenta\u00e7\u00e3o.","og_url":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/","og_site_name":"OYTEC","article_published_time":"2025-10-30T07:50:51+00:00","og_image":[{"width":1632,"height":640,"url":"https:\/\/www.oytec.es\/wp-content\/uploads\/fda-draft-ai-2025.png","type":"image\/png"}],"author":"OYTEC","twitter_card":"summary_large_image","twitter_creator":"@OYTEC_MES","twitter_site":"@OYTEC_MES","twitter_misc":{"Escrito por":"OYTEC","Tempo estimado de leitura":"8 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#article","isPartOf":{"@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/"},"author":{"name":"OYTEC","@id":"https:\/\/oytec.es\/#\/schema\/person\/7139c1ebb2602be7f35ca9e9b357fafa"},"headline":"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos","datePublished":"2025-10-30T07:50:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/"},"wordCount":1607,"publisher":{"@id":"https:\/\/oytec.es\/#organization"},"image":{"@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oytec.es\/wp-content\/uploads\/fda-draft-ai-2025.png","keywords":["2025","Divulga\u00e7\u00e3o","FDA","IA"],"articleSection":["Digitaliza\u00e7\u00e3o","Transforma\u00e7\u00e3o Digital"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/","url":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/","name":"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos OYTEC","isPartOf":{"@id":"https:\/\/oytec.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oytec.es\/wp-content\/uploads\/fda-draft-ai-2025.png","datePublished":"2025-10-30T07:50:51+00:00","description":"Descubra os aspetos-chave do Rascunho de 2025 da FDA sobre a credibilidade da IA farmac\u00eautica e o seu impacto na regulamenta\u00e7\u00e3o.","breadcrumb":{"@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#primaryimage","url":"https:\/\/www.oytec.es\/wp-content\/uploads\/fda-draft-ai-2025.png","contentUrl":"https:\/\/www.oytec.es\/wp-content\/uploads\/fda-draft-ai-2025.png","width":1632,"height":640},{"@type":"BreadcrumbList","@id":"https:\/\/www.oytec.es\/pt\/fda-ia-farmaceutica-rascunho-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.oytec.es\/pt\/"},{"@type":"ListItem","position":2,"name":"A FDA e a IA farmac\u00eautica: aspetos-chave do Rascunho de 2025 sobre a credibilidade dos modelos"}]},{"@type":"WebSite","@id":"https:\/\/oytec.es\/#website","url":"https:\/\/oytec.es\/","name":"OYTEC","description":"Digitalizando las operaciones Farma 4.0","publisher":{"@id":"https:\/\/oytec.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oytec.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/oytec.es\/#organization","name":"OYTEC","url":"https:\/\/oytec.es\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/oytec.es\/#\/schema\/logo\/image\/","url":"https:\/\/oytec.es\/wp-content\/uploads\/2021\/06\/cropped-OYTEC-Logo-transparent.png","contentUrl":"https:\/\/oytec.es\/wp-content\/uploads\/2021\/06\/cropped-OYTEC-Logo-transparent.png","width":175,"height":45,"caption":"OYTEC"},"image":{"@id":"https:\/\/oytec.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/OYTEC_MES","https:\/\/www.linkedin.com\/company\/oytec\/"]},{"@type":"Person","@id":"https:\/\/oytec.es\/#\/schema\/person\/7139c1ebb2602be7f35ca9e9b357fafa","name":"OYTEC","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/secure.gravatar.com\/avatar\/ed13085cc0eeaa48d287170c1bdf9b17c35a4ece8c00f8713ac9b1483411d958?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ed13085cc0eeaa48d287170c1bdf9b17c35a4ece8c00f8713ac9b1483411d958?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ed13085cc0eeaa48d287170c1bdf9b17c35a4ece8c00f8713ac9b1483411d958?s=96&d=mm&r=g","caption":"OYTEC"},"sameAs":["https:\/\/oytec.es"]}]}},"_links":{"self":[{"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/posts\/11019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/comments?post=11019"}],"version-history":[{"count":0,"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/posts\/11019\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/media\/10452"}],"wp:attachment":[{"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/media?parent=11019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/categories?post=11019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oytec.es\/pt\/wp-json\/wp\/v2\/tags?post=11019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}